The West has long labeled Gasdermin proteins "undruggable," effectively stalling the development of therapies targeting cell pyroptosis. While Western biotechs focused on NLRP3, ChinaтАЩs Pyrotech Therapeutics just unlocked the first-ever compounds to successfully modulate the Gasdermin pore.
The science: Unlike apoptosis (quiet cell death), pyroptosis is a "pro-inflammatory" explosion. Controlling it is the holy grail for treating massive indications like CrohnтАЩs, Gout, and even Cancer.
The China Edge: Pyrotech was founded by Academician Shao FengтАФthe man who literally discovered the pyroptosis mechanism. This isn't a "fast-follow" play; it is the global origin of the science. With five FIC (First-in-Class) programs now in clinical stages, they are leading the world in innate immunity.
The latest signal? They just hired Li Tong (ex-Pfizer, Merck, Janssen) as CMO to lead their global MRCT strategy. You don't hire a heavy-hitter CMO with 30 years of Big Pharma experience unless your P1 data is robust enough for a global pivot.
Pyrotech is private, but their success validates the entire
$XBI inflammation sub-sector. Backed by Lilly Asia Ventures, this is the most sophisticated "pure science" play coming out of Beijing right now.
This is the pipeline to watch. ЁЯз╡
$LLY $NVS $SNY $BMY $XBI $IBB